S-1/A: BIOLASE Files for Resale of 4.4 Million Shares Issuable Upon Warrant Exercise

BIOLASE, Inc. has filed a registration statement for the resale of up to 4,443,760 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by a selling stockholder.

Summary

• BIOLASE, Inc. has filed a registration statement on Form S-1 with the SEC to allow a selling stockholder to resell up to 4,443,760 shares of the company's common stock.
• These shares are issuable upon the exercise of warrants, including 2,221,880 December 2023 Warrants and 2,221,880 February 2024 Warrants.
• The December 2023 Warrants were issued in a private placement that closed on December 8, 2023, and the February 2024 Warrants were issued in a private placement that closed on February 15, 2024.
• BIOLASE will not receive any proceeds from the resale of these shares by the selling stockholder, but will receive proceeds from any cash exercise of the Common Warrants.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol BIOL.
• On March 22, 2024, the closing price of BIOLASE's common stock was $0.1793 per share.
• The selling stockholder may be deemed an underwriter and may sell shares through public or private transactions at prevailing market prices or negotiated prices.
• The company has agreed to bear the expenses related to the registration of these shares.
• The selling stockholder will pay any commissions or discounts related to their sales of the common stock.
• The company had net revenues of $49.2 million in 2023 and a net loss of $20.6 million for the same period.

Sentiment

Score: 4

Explanation: The document primarily focuses on the registration of shares for resale, which is a neutral event. However, the company's history of net losses and the risks associated with its business model contribute to a slightly negative sentiment.

Positives

• The registration statement fulfills contractual obligations with the selling stockholder.
• The company will receive proceeds from any cash exercise of the Common Warrants, which it intends to use for working capital purposes.
• The company's net revenues increased from $39.2 million in 2021 to $49.2 million in 2023.

Negatives

• BIOLASE will not receive any proceeds from the resale of shares by the selling stockholder.
• The company has a history of net losses, with a net loss of $20.6 million in 2023.
• The company's stock price is low, with a closing price of $0.1793 on March 22, 2024.

Risks

• The market price of the company's common stock may be volatile.
• The company may need to raise additional capital in the future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company could be subject to significant warranty obligations if its products are defective.
• Failure to meet Nasdaq's continued listing requirements could result in the delisting of the company's common stock.

Future Outlook

The company intends to use the proceeds from any cash exercise of the Common Warrants for working capital purposes.

Industry Context

BIOLASE operates in the dental laser systems market, competing with companies offering traditional dental instruments and other laser technologies. The company emphasizes the benefits of its laser systems, such as less pain, faster healing, and improved patient care.

Comparison to Industry Standards

• It is difficult to compare BIOLASE directly to industry standards without detailed financial benchmarks of competitors in the dental laser market.
• Companies like AMD LASERS and Convergent Dental are also players in this space, but their financial disclosures may not be directly comparable.
• BIOLASE's revenue and losses should be benchmarked against these competitors to assess its relative performance.

Stakeholder Impact

• The resale of shares could potentially dilute existing shareholders.
• The company's ability to execute its business plan and achieve profitability will impact its employees and customers.
• The company's financial performance will affect its creditors and suppliers.

Next Steps

• The selling stockholder may offer and sell the shares of common stock from time to time.
• The company needs to obtain stockholder approval for the issuance of shares upon exercise of the Common Warrants.
• The company intends to monitor the closing bid price of its Common Stock and may consider available options to regain compliance with the Bid Price Rule.

Key Dates

Keywords

BIOLASE, common stock, warrants, resale, registration statement, private placement, selling stockholder, dental lasers, BIOL, offering